Chris McNally
Chris McNally, PhD, has a strong foundation in Biomedical Science, earning his BSc from Ulster University and completing a PhD scholarship in collaboration with Randox Laboratories and Ulster University. Chris has published extensively in prostate cancer research, focusing on biomarker discovery, cancer risk stratification, and molecular mechanisms such as hypoxia-induced regulation. He currently serves as a Business Development Manager at Assay Genie.
Connect with Chris or explore his work:
Blogs by Chris:
What You Need to Know About VarlilumabWhat is Varlilumab?Varlilumab is a monoclonal antibody targeting CD27, a receptor on T-cells that plays a critical role in immune modulation.What is the mechanism of action for Varlilumab?Varlilumab enhances immune responses by activating CD27 signaling, promoting T-cell [...]
What You Need to Know About IfabotuzumabWhat is Ifabotuzumab?Ifabotuzumab is a monoclonal antibody targeting EphA3, a receptor tyrosine kinase overexpressed in certain cancers. It plays a critical role in tumor angiogenesis and microenvironment regulation.What is the mechanism of action for Ifabotuzumab?Ifabotuzumab binds to [...]
What You Need to Know About IscalimabWhat is Iscalimab?Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key protein involved in immune system regulation.What is the mechanism of action for Iscalimab?Iscalimab blocks the CD40-CD40L pathway, preventing the activation of T cells and B [...]
Publications by Chris: